Status:
TERMINATED
Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer
Lead Sponsor:
Centre Oscar Lambret
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
L'Institut des sciences moléculaires (iSm2 UMR CNRS 7313)
Conditions:
Cancer of Rectum
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational, single-centre study (RIPH3) for patients with rectal cancer soon to be treated with chemotherapy (+/- neo-adjuvant radio-chemotherapy) looking at the relationship between the...
Detailed Description
Main objective: The main objective is to test the association between : * the gut microbiota assessed from a stool sample before the start of neoadjuvant treatment of patients (T0) on the one hand, a...
Eligibility Criteria
Inclusion
- Histologically proven stage II and III adenocarcinoma of the lower and middle rectum
- Patient undergoing preoperative treatment with induction chemotherapy (Folfirinox) followed or not by radio-chemotherapy of the Cap50 type
- Male or female patient aged 18 years or older
- Normal weight, overweight or moderately obese (BMI between 18.5 and 34.9)
- Patient residing in the Lille metropolitan area
- Patient affiliated to a French social protection scheme
- Patient having given his non-opposition
Exclusion
- History of other concurrent cancers
- Presence of an intestinal (internal or external) or external urinary diversion
- Uncooperative patient for geographical, family, social or psychological reasons
- Limited legal capacity or legal incapacity
Key Trial Info
Start Date :
January 19 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 8 2024
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT06181201
Start Date
January 19 2024
End Date
October 8 2024
Last Update
December 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Oscar Lambret
Lille, France, 59000